For instance, the anti-PD-1 nivolumab, as second-line therapy in advanced NSCLC compared with docetaxel, was reported to improve the response rate and overall survival in two randomized phase III trials (22, 23). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.